SISVEL
9.11.2022 10:01:36 CET | Business Wire | Press release
Sisvel International S.A. (Sisvel) announced today the launch of its Cellular IoT (C-IoT) Patent Pool consisting of 20 patent owners.
The C-IoT patent pool offers a single solution to license standard essential patents (SEPs) that are essential for the use of the cellular LPWAN standards LTE-M and Narrowband IoT (NB-IoT). Sisvel is joined in the pool by ASUSTek, Datang, Ericsson, ETRI, Innovative Sonic, JVCKENWOOD, KDDI, MediaTek, Mitsubishi Electric, NTT DOCOMO, Optis Cellular, Optis Wireless, Orange, Pantech, Shanghai Langbo, Sony Group Corporation, Telefónica, Unwired Planet and one additional company to be announced soon. The pool remains open for new participants that hold relevant patents. The C-IoT pool’s initial main focus will be on smart meters and asset trackers.
“The IoT market has been in development for about a decade, however only now we see clear early signs of widespread roll-out.” said Mattia Fogliacco, President of the Sisvel Group. He continues: “The LTE-M and NB-IoT technologies are an obvious pick to connect products and services, and with this pool, available already in an early phase of technology adoption, we will remove a lot of questions and concerns by giving easy, transparent and reasonable access to the patents that the creators of the technology hold.”
“It has been a pleasure putting this pool together, as so many parties with diverse background and business models showed resolve and common interest in creating a pool in the LPWAN IoT space.” said Sven Törringer, the program manager of the Sisvel C-IoT patent pool. He added: “This has been a harmonious process and we are convinced that the offer we bring to the market will not only reduce friction and concerns, but rather boost the interest in the adoption of the LTE-M and NB-IoT standards in IoT products, allowing for swift investments in this sense.”
LTE-M and NB-IoT are cellular LPWAN IoT standards that followed out of the 4G LTE standard. They offer a solution for low power connectivity of IoT products, that may compete with the functionality offered by a number of other technologies, such as LoRaWAN, Sigfox, WiFi, MIOTY, Bluetooth, various mesh network technologies, etc, and combinations thereof. By offering a clear framework for obtaining licenses under the pool’s portfolio of LTE-M and NB-IoT SEPs, Sisvel is making it easier for manufacturers of IoT devices to make a balanced choice between the available technologies. The Sisvel pool has committed itself to make the terms of LTE-M and NB-IoT competitive, to encourage the use of the LPWAN cellular IoT standards, helping to achieve a level playing field.
Further information about the C-IoT patent pool is available on Sisvel’s website: https://www.sisvel.com/licensing-programs/wireless-communications/cellular-iot/introduction. For more details you may contact Sisvel at the following e-mail address ciot@sisvel.com.
About Sisvel
Sisvel International S.A. is the holding company of the Sisvel Group. Sisvel is a world leader in fostering innovation and managing IP. The group identifies, evaluates and maximizes the value of IP assets for its partners around the world, providing firms with a revenue stream which can be reinvested in innovation for the generation of future revenues. Sisvel has 40 years’ experience in the management of successful patent portfolios, including those relating to audio compression standards (MP3 and MPEG audio), as well as broadcasting and digital terrestrial television standards maintained by the Digital Video Broadcasting Project. Currently Sisvel operates patent pools and joint licensing programs in the fields of mobile communication, wireless local area networking 802.11, video coding and digital video broadcasting.
www.sisvel.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005073/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom